BRF
RARE icon

B. Riley Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

B. Riley Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,600
Closed -$213K – 325
2017
Q4 		$213K Buy
+4,600
New +$226K 0.06% 273

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

B. Riley Financial's RARE Position: Q1 2018 in Review

B. Riley Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 4,600 shares — an estimated $213K sold.

B. Riley Financial first reported a position in RARE in Q4 2017 and held it in 1 quarter. The position peaked at $213K in Q4 2017. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

  • B. Riley Financial reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • B. Riley Financial sold 4,600 Ultragenyx Pharmaceutical shares in Q1 2018, an estimated $213K.
  • B. Riley Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • B. Riley Financial's Ultragenyx Pharmaceutical position peaked at $213K in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on B. Riley Financial's 13F filing for Q1 2018, filed 4 May 2018.